BriaCell Therapeutics Corp. - Common Shares (BCTX)
BCTX moved a median of -0.79% 30 minutes after news, and -1.47% by the close. How BCTX actually reacts to news — the realized, point-in-time move the market made, measured across 252 labeled events over the last three years with zero look-ahead.
BCTX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.12% | 39% | 248 |
| 30-min | -0.79% | 38% | 251 |
| 60-min | -1.25% | 35% | 252 |
| to close | -1.47% | 35% | 251 |
| Middle 50% of BCTX reactions | -3.30% to +1.18% |
|---|---|
| Median reaction (30-min) | -0.79% |
| Measured reactions | 252 |
Half of all BriaCell Therapeutics Corp. - Common Shares news events land between -3.30% and +1.18% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when BCTX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to BCTX's baseline. Nothing else.
Recent BCTX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting | Press release | GlobeNewswire | -0.10% | -4.29% | |
| Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study | Press release | GlobeNewswire | +0.28% | -0.56% | |
| BriaCell’s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center | Press release | GlobeNewswire | -2.24% | +0.14% | |
| BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™ | Press release | GlobeNewswire | -4.95% | -14.36% | |
| BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer | Press release | GlobeNewswire | -1.68% | -2.23% | |
| BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer | Press release | GlobeNewswire | -1.52% | -1.53% | |
| BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™ | Press release | GlobeNewswire | +1.89% | +6.20% | |
| BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™ | Press release | GlobeNewswire | +1.61% | -2.24% | |
| Form 8-K BriaCell Therapeutics For: Jun 26 | SEC filing · Form 8-K | SEC EDGAR | -0.64% | -0.64% | |
| BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™ | Press release | GlobeNewswire | +1.29% | -4.50% | |
| Form 10-Q BriaCell Therapeutics For: Apr 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.00% | -4.32% | |
| Form 8-K BriaCell Therapeutics For: May 31 | SEC filing · Form 8-K | SEC EDGAR | -1.49% | +0.92% | |
| BriaCell Therapeutics Announces Closing of Offering | Press release | GlobeNewswire | -1.49% | +0.92% | |
| BriaCell Presents Positive Clinical Data at ASCO 2026 | Press release | GlobeNewswire | -0.91% | +0.00% | |
| BriaCell Therapeutics Announces Pricing of Offering | Press release | GlobeNewswire | -0.91% | +0.00% | |
| BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer | Press release | GlobeNewswire | +0.00% | -2.01% | |
| BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026 | Press release | GlobeNewswire | +0.29% | +1.16% | |
| BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™ | Press release | GlobeNewswire | +0.75% | -24.12% | |
| BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer | Press release | GlobeNewswire | +0.73% | -1.22% | |
| BriaCell Adds Penn Medicine’s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study | Press release | GlobeNewswire | +2.42% | +1.21% | |
| BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients | Press release | GlobeNewswire | -0.72% | -2.39% | |
| BriaCell Adds NYU Langone Health’s Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study | Press release | GlobeNewswire | -2.15% | -1.91% | |
| BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer | Press release | GlobeNewswire | -0.96% | +0.00% | |
| BriaCell Announces Six Clinical Data Presentations at ASCO 2026 | Press release | GlobeNewswire | +1.29% | +3.87% | |
| BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models | Press release | GlobeNewswire | -1.91% | -2.68% | |
| BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting | Press release | GlobeNewswire | -1.81% | -9.26% | |
| BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License | Press release | GlobeNewswire | +0.00% | -0.24% | |
| Form 8-K BriaCell Therapeutics For: Mar 31 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.24% | |
| BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference | Press release | GlobeNewswire | -0.89% | -3.79% | |
| BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting | Press release | GlobeNewswire | +2.39% | +1.33% | |
| Form 10-Q BriaCell Therapeutics For: Jan 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.52% | +13.61% | |
| Form 8-K BriaCell Therapeutics For: Mar 05 | SEC filing · Form 8-K | SEC EDGAR | +2.39% | +1.33% | |
| BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting | Press release | GlobeNewswire | +0.00% | -2.52% | |
| Form 8-K BriaCell Therapeutics For: Feb 18 | SEC filing · Form 8-K | SEC EDGAR | -2.56% | -3.59% | |
| BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License | Press release | GlobeNewswire | +0.75% | +2.74% | |
| BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer | Press release | GlobeNewswire | -5.80% | -1.98% | |
| Form DEF 14A BriaCell Therapeutics For: Feb 12 | SEC filing · Form DEF | SEC EDGAR | +1.23% | -0.24% | |
| BriaCell Patients’ Images Show Regression and Resolution of Metastasized Tumors and Immune Activation | Press release | GlobeNewswire | +0.61% | -5.07% | |
| BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients | Press release | GlobeNewswire | -1.41% | +6.30% | |
| BriaCell Therapeutics Announces Closing of US$30 million Public Offering | Press release | GlobeNewswire | -0.90% | -4.67% | |
| Form 8-K BriaCell Therapeutics For: Jan 13 | SEC filing · Form 8-K | SEC EDGAR | -0.90% | -4.67% | |
| Form EFFECT BriaCell Therapeutics | SEC filing · Form EFFECT | SEC EDGAR | +5.83% | +1.25% | |
| BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient | Press release | GlobeNewswire | -13.25% | -9.00% | |
| BriaCell Therapeutics Announces Pricing of $30 million Public Offering | Press release | GlobeNewswire | +5.83% | +1.25% | |
| Form 8-A12B BriaCell Therapeutics | SEC filing · Form 8-A12B | SEC EDGAR | -1.07% | +7.82% | |
| Form CERT BriaCell Therapeutics | SEC filing · Form CERT | SEC EDGAR | +5.83% | +1.25% | |
| Form S-1MEF BriaCell Therapeutics | SEC filing · Form S-1MEF | SEC EDGAR | +5.83% | +1.25% | |
| How $594B in Precision Tech is Cracking the Metastatic Cancer Code | Press release | PR Newswire | -2.32% | -1.35% | |
| Form 8-K BriaCell Therapeutics For: Dec 29 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +6.90% | |
| Form S-1 BriaCell Therapeutics | SEC filing · Form S-1 | SEC EDGAR | -3.77% | +9.58% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the BCTX section they belong to.
Where else BCTX is measured.
BCTX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is BriaCell Therapeutics Corp. - Common Shares's median reaction calculated?
Every labeled BCTX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 252 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 38% of BCTX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does BCTX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.